CN114470050A

CN114470050A - Traditional Chinese medicine compound composition

Info

Publication number: CN114470050A
Application number: CN202210277824.8A
Authority: CN
Inventors: 尹雅婷; 杨娜; 程康; 吕智
Original assignee: Shanghai Inoherb Cosmetic Co ltd
Current assignee: Shanghai Inoherb Cosmetic Co ltd
Priority date: 2022-03-21
Filing date: 2022-03-21
Publication date: 2022-05-13
Anticipated expiration: 2042-03-21
Also published as: CN114470050B

Abstract

The invention provides a traditional Chinese medicine compound composition, which contains cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and/or saxifrage as extracts of raw material medicines. The invention also provides a method for preparing the traditional Chinese medicine compound composition. The traditional Chinese medicine compound composition can be used for skin care, and is particularly used for preventing and relieving allergy, inflammation, redness, irritation and itching pain. The invention also relates to application of the traditional Chinese medicine compound composition in preparing products for resisting allergy, resisting inflammation, relieving redness, relieving itching, resisting irritation and/or repairing skin.

Description

Traditional Chinese medicine compound composition

Technical Field

The invention relates to a traditional Chinese medicine compound composition, in particular to a traditional Chinese medicine compound composition for resisting allergy, resisting inflammation, relieving redness, relieving itching, resisting irritation and/or repairing skin, and more particularly to a traditional Chinese medicine compound composition for resisting allergy. The traditional Chinese medicine compound composition contains the extracts of the cortex moutan, the honeysuckle, the radix sophorae flavescentis, the cortex dictamni and/or the saxifrage, can be used for skin care, and is particularly used for preventing and relieving skin allergy, skin inflammation, skin allergy, skin redness, skin irritation and itching and pain. The invention also relates to a preparation method of the traditional Chinese medicine compound composition and application of the traditional Chinese medicine compound composition in preparing products for resisting allergy, resisting inflammation, relieving redness, relieving itching, resisting irritation and/or repairing skin. The invention further relates to a pharmaceutical preparation or a cosmetic containing the traditional Chinese medicine compound composition.

Background

With the increasingly poor environment, excessive use of poor cosmetics and the like, the proportion of problems to the skin, such as inflammation, red swelling, allergy, chapping, itching and pain, is higher, and how to solve the problems of the skin has great practical significance.

Cortex moutan: moutan bark, cortex moutan, is the dried root bark of Paeonia suffruticosa Andr. Has the effects of promoting blood circulation, removing blood stasis, clearing away heat, etc. Research shows that the cortex moutan extract can inhibit early inflammatory reaction mainly including telangiectasia, permeability increase and exudative edema. Professor Stazeri prepares "three-skin itching relieving decoction (capsule)" and "three-skin acne eliminating decoction" with cortex Mori, cortex Lycii and cortex moutan as main materials, and is used for treating skin diseases.

Honeysuckle flower: also known as honeysuckle flower, is a dried bud or a flower with an initial bloom of Lonicera japonica Thunb. It is known as a good herb for clearing heat and removing toxicity from ancient times. Researches show that the honeysuckle extract mainly contains volatile oil, flavonoid, organic acid, triterpenes and inorganic elements, can be used as raw materials of medicines, health-care products and cosmetics, and mainly has the effects of inhibiting bacteria, relieving allergy, delaying aging, preventing ultraviolet injury and the like.

Flavescent sophora root: is dried root of Sophora flavescens ait. Has effects of clearing heat and eliminating dampness, and can be used for treating eczema, and skin pruritus. Research shows that the sophora flavescens extract can inhibit inflammatory cell infiltration of rats and has obvious functions of resisting inflammation and reducing capillary permeability.

And (3) preparing cortex dictamni: is dried root bark of Dictamnus dasycarpus of Rutaceae. Has effects of clearing heat, eliminating dampness, dispelling pathogenic wind, and removing toxic substance, and can be used for treating skin sore, eczema, and rubella due to damp-heat. Research shows that the product has various activities of antibiosis, anti-inflammation, antianaphylaxis, antioxidation, etc.

Saxifrage: is Saxifraga stolonifera Curtis which is a perennial herb and belongs to the Saxifraga stolonifera Curtis. The saxifrage has the effects of dispelling wind, clearing heat, cooling blood and removing toxicity, and also has various medicinal values of antibiosis, anti-inflammation, antioxidation, anti-tumor and the like. Research shows that the saxifrage extract has antioxidant effect similar to that of vitamin C in high concentration and has tyrosinase activity inhibiting effect.

The current research begins to focus on the field of safer traditional Chinese medicines, but many commercially available anti-skin allergy agents (particularly cosmetics) have the problems that the efficacy does not achieve the expected purpose, the product is unstable, and great troubles are brought to users. Therefore, there is a strong need for a Chinese medicinal composition with definite and safe effect, no adverse reaction, and effects of resisting allergy, resisting inflammation, relieving redness, relieving itching, resisting irritation and/or repairing skin.

Disclosure of Invention

The invention solves the problems in the prior art by the traditional Chinese medicine compound composition containing cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and/or saxifrage, the preparation method and the application thereof. The invention provides a powerful traditional Chinese medicine compound composition with the functions of resisting allergy, resisting inflammation, relieving redness, relieving itching, resisting irritation and/or repairing skin. The traditional Chinese medicine compound composition contains cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and/or saxifrage. The traditional Chinese medicine compound composition can be used for skin care, and is particularly used for preventing and relieving skin allergy, skin inflammation, skin allergy, skin redness, skin irritation and itching pain.

In a first aspect, the present invention relates to a compound Chinese medicinal composition, which comprises or consists of cortex moutan, flos lonicerae, radix sophorae flavescentis, cortex dictamni and/or saxifrage.

In some embodiments, in the herbal compound composition of the present invention, the composition contains the following raw material drugs by weight: 0-40% of cortex moutan, 0-60% of honeysuckle, 0-60% of radix sophorae flavescentis, 0-80% of cortex dictamni and/or 0-40% of saxifrage; or consist of them.

In a second aspect, the present invention relates to a method for preparing a compound Chinese medicinal composition, which contains the raw materials described in the first aspect and their weight percentages.

In some embodiments, the preparation method of the traditional Chinese medicine compound composition comprises the following steps: weighing and crushing raw material medicines, wherein the raw material medicines comprise cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and/or saxifrage; extracting pulverized raw materials with water, extracting with 10% -70% C2-6 alcohol aqueous solution, and mixing the two extracts to obtain extract composition. In some embodiments, the method further comprises purifying the obtained extract composition by filtration, and obtaining a concentrated solution, i.e., the herbal compound composition of the present invention.

In some embodiments, the preparation method of the traditional Chinese medicine compound composition comprises the following steps: respectively weighing cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni Radicis and/or herba Saxifragae, and pulverizing; the crushed raw material medicines are respectively extracted according to the following methods: extracting with water, extracting with 10% -70% C2-6 alcohol aqueous solution, and mixing the two extracts to obtain separate extracts of the raw materials. In some embodiments, the method further comprises purifying each of the individual bulk drug extracts by filtration and obtaining a concentrate, and mixing each of the individual bulk drug extracts in the following weight percentages: 0-40% of cortex moutan, 0-60% of honeysuckle, 0-60% of radix sophorae flavescentis, 0-80% of cortex dictamni and/or 0-40% of saxifrage, and then the traditional Chinese medicine compound composition is obtained.

A third aspect of the present invention relates to the traditional Chinese medicine compound composition of the present invention obtained by the preparation method as defined in the second aspect of the present invention. In some embodiments, the herbal composition comprises moutan bark, lonicera japonica, sophora flavescens, dictamnus dasycarpus and/or saxifrage. Further, the traditional Chinese medicine compound composition is as defined in the first aspect of the invention.

In a fourth aspect, the present invention relates to a herbal composition for anti-allergy, anti-inflammatory, redness relief, itching relief, anti-irritation and/or skin repair. In some embodiments, the herbal compound composition is as defined in the first aspect of the invention. In some embodiments, the herbal compound composition is a herbal compound composition obtained by the preparation method as defined in the third aspect of the present invention.

In a fifth aspect, the invention relates to the use of a herbal combination in a product for anti-allergy, anti-inflammatory, redness relief, itching relief, anti-irritation and/or skin repair. In some embodiments, the herbal compound composition is as defined in the first aspect of the invention. In some embodiments, the herbal compound composition is a herbal compound composition obtained by the preparation method as defined in the third aspect of the present invention. In some embodiments, the product is a pharmaceutical formulation or a cosmetic.

In a sixth aspect, the present invention relates to a pharmaceutical preparation or a cosmetic, wherein the pharmaceutical preparation or the cosmetic comprises a herbal composition comprising or consisting of cortex moutan, flos lonicerae, radix sophorae flavescentis, cortex dictamni and/or saxifrage.

In a seventh aspect, the present invention relates to a cosmetic method comprising applying a herbal composition comprising cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni Radicis and/or herba Saxifragae.

Drawings

FIG. 1 shows the inhibitory effect of different concentrations of the herbal compound compositions of example 3 and comparative examples 1-4 on the inflammatory factor IL-8.

FIG. 2 shows the inhibitory effect of different concentrations of the herbal compound compositions of example 3 and comparative examples 1-4 on NF-kb.

FIG. 3 shows the effect of different concentrations of the herbal composition of example 3 and comparative examples 1-4 on the change in the degree of redness of the skin of a human body after 24 hours.

Detailed Description

Definition of

The terms "herbal composition", "herbal combination" and "composition" as used herein have similar meanings and may be used interchangeably unless otherwise specified. The terms "wt%" and "weight percent" are used interchangeably herein, and unless otherwise specified, percent refers to weight percent.

The term "room temperature" as used herein means 25 ℃. + -. 1 ℃. Meanwhile, if the experimental temperature is not specified, the temperature is room temperature.

The terms "s", "min" and "h" as used herein represent "seconds", "minutes" and "hours", respectively.

The term "about" as used herein means ± 10%, more preferably ± 5%, and most preferably ± 2% of the numerical value modified by the term, and thus the range of the term "about" can be clearly determined by one of ordinary skill in the art according to the modified numerical value.

The term "consisting of cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni and/or herba Saxifragae" as used herein means that no active ingredient is contained except the limited cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni and/or herba Saxifragae, but auxiliary ingredients such as adjuvants, excipients and carriers are not excluded.

The term "pulverizing the raw material drugs" as used herein means pulverizing cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni Radicis and/or herba Saxifragae together or separately.

In some embodiments, the cortex moutan, the flos lonicerae, the radix sophorae flavescentis, the cortex dictamni and/or the saxifrage in the traditional Chinese medicine compound composition are selected from the following raw materials in percentage by weight: 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 33.3%, 33.4%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, (all inclusive), 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, and 99%, and ranges between any of the foregoing weight percentages, for example, in the Chinese herbal compound composition of the present invention, the composition contains the following raw material drugs in weight percentage: 0-40% of cortex moutan, 0-60% of honeysuckle, 0-60% of radix sophorae flavescentis, 0-80% of cortex dictamni and/or 0-40% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicines in percentage by weight: 10-30% of cortex moutan, 20-40% of honeysuckle, 20-40% of radix sophorae flavescentis, 20-60% of cortex dictamni and 0-20% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicines in percentage by weight: 10-30% of cortex moutan, 20-40% of honeysuckle, 20-40% of radix sophorae flavescentis, 20-60% of cortex dictamni and 2-8% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicines in percentage by weight: 12-28% of cortex moutan, 20-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and/or 2-8% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicines in percentage by weight: 12-24% of cortex moutan, 20-28% of honeysuckle, 20-24% of radix sophorae flavescentis, 20-28% of cortex dictamni and/or 2-6% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicines in percentage by weight: 18-24% of cortex moutan, 20-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and/or 2-8% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicines in percentage by weight: 12-24% of cortex moutan, 28-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and/or 2-8% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicines in percentage by weight: 12-24% of cortex moutan, 28-32% of honeysuckle, 24-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and/or 2-8% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicines in percentage by weight: 12-24% of cortex moutan, 28-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 24-28% of cortex dictamni and/or 2-8% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicines in percentage by weight: 12-24% of cortex moutan, 28-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and/or 4-6% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicines in percentage by weight: 12% of cortex moutan, 32% of honeysuckle, 20% of radix sophorae flavescentis, 36% of cortex dictamni and/or 2% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicines in percentage by weight: cortex moutan 18%, flos Lonicerae 20%, radix Sophorae Flavescentis 28%, cortex Dictamni Radicis 28% and/or herba Saxifragae 6%; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicines in percentage by weight: cortex moutan 24%, flos Lonicerae 28%, radix Sophorae Flavescentis 20%, cortex Dictamni Radicis 24% and/or herba Saxifragae 4%; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicines in percentage by weight: cortex moutan 28%, flos Lonicerae 20%, radix Sophorae Flavescentis 24%, cortex Dictamni Radicis 20% and/or herba Saxifragae 8%; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicines in percentage by weight: cortex moutan 24%, flos Lonicerae 28%, radix Sophorae Flavescentis 20%, cortex Dictamni Radicis 24% and/or herba Saxifragae 4%; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicines in percentage by weight: cortex moutan 18%, flos Lonicerae 20%, radix Sophorae Flavescentis 28%, cortex Dictamni Radicis 28% and herba Saxifragae 6%; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicines in percentage by weight: cortex moutan 24%, flos Lonicerae 28%, radix Sophorae Flavescentis 20%, cortex Dictamni Radicis 24% and herba Saxifragae 4%; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicines in percentage by weight: cortex moutan 28%, flos Lonicerae 20%, radix Sophorae Flavescentis 24%, cortex Dictamni Radicis 20% and herba Saxifragae 8%; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicines in percentage by weight: cortex moutan 24%, flos Lonicerae 28%, radix Sophorae Flavescentis 20%, cortex Dictamni Radicis 24% and herba Saxifragae 4%; or consist of them.

In some embodiments, the preparation method of the traditional Chinese medicine compound composition comprises the following steps: respectively weighing cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni Radicis and/or herba Saxifragae, and pulverizing; the crushed raw material medicines are respectively extracted according to the following methods: extracting with water, extracting with 10% -70% C2-6 alcohol aqueous solution, and mixing the two extracts to obtain separate extracts of the raw materials. In some embodiments, the method further comprises purifying the obtained individual crude drug extracts by filtration to obtain concentrated solutions, and mixing the cortex moutan extract, the honeysuckle extract, the radix sophorae flavescentis extract, the cortex dictamni extract and/or the saxifrage extract according to a certain weight percentage to obtain the traditional Chinese medicine compound composition of the present invention. Specifically, the certain proportion is selected from the following weight percentages: 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 33.3%, 33.4%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, (all inclusive), 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, and 99%, and ranges between any of the foregoing weight percentages, for example, in the herbal compound composition of the present invention, the composition contains the following herbal extracts in weight percentages: 0-40% of cortex moutan, 0-60% of honeysuckle, 0-60% of radix sophorae flavescentis, 0-80% of cortex dictamni and/or 0-40% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: 10-30% of cortex moutan, 20-40% of honeysuckle, 20-40% of radix sophorae flavescentis, 20-60% of cortex dictamni and 0-20% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: 10-30% of cortex moutan, 20-40% of honeysuckle, 20-40% of radix sophorae flavescentis, 20-60% of cortex dictamni and 2-8% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: 12-28% of cortex moutan, 20-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and/or 2-8% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: 12-24% of cortex moutan, 20-28% of honeysuckle, 20-24% of radix sophorae flavescentis, 20-28% of cortex dictamni and/or 2-6% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: 18-24% of cortex moutan, 20-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and/or 2-8% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: 12-24% of cortex moutan, 28-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and/or 2-8% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: 12-24% of cortex moutan, 28-32% of honeysuckle, 24-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and/or 2-8% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: 12-24% of cortex moutan, 28-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 24-28% of cortex dictamni and/or 2-8% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: 12-24% of cortex moutan, 28-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and/or 4-6% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: 12% of cortex moutan, 32% of honeysuckle, 20% of radix sophorae flavescentis, 36% of cortex dictamni and/or 2% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: cortex moutan 18%, flos Lonicerae 20%, radix Sophorae Flavescentis 28%, cortex Dictamni Radicis 28% and/or herba Saxifragae 6%; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: cortex moutan 24%, flos Lonicerae 28%, radix Sophorae Flavescentis 20%, cortex Dictamni Radicis 24% and/or herba Saxifragae 4%; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: cortex moutan 28%, flos Lonicerae 20%, radix Sophorae Flavescentis 24%, cortex Dictamni Radicis 20% and/or herba Saxifragae 8%; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: cortex moutan 24%, flos Lonicerae 28%, radix Sophorae Flavescentis 20%, cortex Dictamni Radicis 24% and/or herba Saxifragae 4%; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: cortex moutan 18%, flos Lonicerae 20%, radix Sophorae Flavescentis 28%, cortex Dictamni Radicis 28% and herba Saxifragae 6%; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: cortex moutan 24%, flos Lonicerae 28%, radix Sophorae Flavescentis 20%, cortex Dictamni Radicis 24% and herba Saxifragae 4%; in the traditional Chinese medicine compound composition, the composition contains the following crude drug extracts in percentage by weight: cortex moutan 28%, flos Lonicerae 20%, radix Sophorae Flavescentis 24%, cortex Dictamni Radicis 20% and herba Saxifragae 8%; in the traditional Chinese medicine compound composition, the composition contains the following crude drug extracts in percentage by weight: cortex moutan 24%, flos Lonicerae 28%, radix Sophorae Flavescentis 20%, cortex Dictamni Radicis 24% and herba Saxifragae 4%; or consist of them. In some embodiments, the concentrates are adjusted with water. Further, each of the concentrates is adjusted to a desired amount, for example, 1000g, with water.

In some embodiments, the extract composition is filtered through a filter membrane for purification and a concentrate is obtained. In some embodiments, the filtrate is recovered by filtration using a 5000-. In some embodiments, the solvent is recovered by filtration using a 100-.

In some embodiments, the extract of the present invention is a water and/or C2-6 alcohol extract, and the solvent for extraction is water, C2-6 alcohol, or a combination thereof. In some embodiments, the C2-6 alcohol is ethanol, propanol, propylene glycol, n-butanol, or a combination thereof, preferably propylene glycol and ethanol. In some embodiments, the drug substance is pulverized, extracted with water, then extracted with a 10% to 70% aqueous solution of C2-6 alcohol, and the two extracts are combined to obtain the extract composition. In a further preferred embodiment, the extract composition is obtained by first extracting a pulverized raw material with an aqueous solution of 10% -50% C2-6 alcohol and mixing the two extracts.

In some embodiments, the drug substance is pulverized, extracted with water, then extracted with a 10% to 70% aqueous solution of propylene glycol and/or ethanol, and the two extracts are mixed to obtain the extract composition. In some embodiments, the drug substance is pulverized, extracted with water, then extracted with a 10% -50% aqueous solution of propylene glycol and/or ethanol, and the two extracts are mixed to obtain the extract composition.

In some embodiments, the method comprises pulverizing the raw materials into 10-20 mesh coarse powder, adding 5-10 times of water, and extracting at 50-90 deg.C to obtain extractive solution A1. Extracting the residue with 2-10 times of ethanol, propanol, propylene glycol, n-butanol or their combination at 50-90 deg.C to obtain extractive solution A2. Mixing the extractive solutions A1 and A2, filtering, and recovering solvent to obtain concentrated solution. In some embodiments, the extract composition is filtered through a filter membrane for purification and a concentrate is obtained. In some embodiments, the filtrate is recovered by filtration using a 5000-. In some embodiments, the solvent is recovered by filtration using a 100-.

In some embodiments, the method comprises pulverizing the raw materials into 10-20 mesh coarse powder, adding 5-10 times of water, extracting at 50-90 deg.C to obtain extractive solution A1; extracting the residue with 2-10 times of ethanol, propanol, propylene glycol, n-butanol or their combination at 50-90 deg.C to obtain extractive solution A2. Mixing the extractive solutions A1 and A2, filtering, and recovering solvent to obtain concentrated solution. In some embodiments, the drug substance is pulverized into a coarse powder of 10 mesh or 20 mesh. In some embodiments, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times or a range therebetween of water is added for extraction at 50 ℃, 60 ℃, 70 ℃, 80 ℃, 90 ℃ or a range therebetween to obtain extract a 1. In some embodiments, the residue is extracted with 2 times, 3 times, 4 times or a range therebetween of ethanol or propylene glycol or a mixture of ethanol and propylene glycol (at a ratio of 1:1) at 50 ℃, 55 ℃, 60 ℃, 65 ℃, 70 ℃, 80 ℃, 90 ℃ or a range therebetween to obtain extract a 2. In some embodiments, the ethanol or propylene glycol or mixture of ethanol and propylene glycol (at 1:1 volume percent) is 10% to 70% ethanol or propylene glycol or mixture of ethanol and propylene glycol (at 1:1 volume percent). In some embodiments, the ethanol or propylene glycol or mixture of ethanol and propylene glycol (at 1:1 volume percent) is 10%, 20%, 30%, 40%, 50% or a range therebetween of ethanol or propylene glycol or mixture of ethanol and propylene glycol (at 1:1 volume percent). In some embodiments, the concentrate is adjusted to 1000g with water, i.e. representing 100% strength of the extract.

In some embodiments, the method comprises pulverizing the raw materials into 10 mesh coarse powder, adding about 6 times of water, extracting at about 60 deg.C to obtain extractive solution A1; extracting the residue with about 3 times of about 40% propylene glycol at about 70 deg.C to obtain extractive solution A2. Mixing the extractive solutions A1 and A2, filtering, and recovering solvent to obtain concentrated solution.

In some embodiments, the method comprises pulverizing the raw materials into 20 mesh coarse powder, adding about 5 times of water, extracting at about 80 deg.C to obtain extractive solution A1; extracting the residue with about 3 times of about 40% ethanol at about 65 deg.C to obtain extractive solution A2. Mixing the extractive solutions A1 and A2, filtering, and recovering solvent to obtain concentrated solution.

In some embodiments, the method comprises pulverizing the raw materials into 20 mesh coarse powder, adding about 5 times of water, extracting at about 60 deg.C to obtain extractive solution A1; extracting the residue with about 4 times of mixed solvent of 10% ethanol and 40% propylene glycol at 1:1 ratio at 70 deg.C to obtain extractive solution A2. Mixing the extractive solutions A1 and A2, filtering, and recovering solvent to obtain concentrated solution.

In some embodiments, the method comprises pulverizing the raw materials into 20 mesh coarse powder, adding about 5 times of water, extracting at about 70 deg.C to obtain extractive solution A1; extracting the residue with about 4 times of mixed solvent of 40% ethanol and 10% propylene glycol at 1:1 ratio at 55 deg.C to obtain extractive solution A2. Mixing the extractive solutions A1 and A2, filtering, and recovering solvent to obtain concentrated solution.

In some embodiments, the method comprises pulverizing the raw materials into 10 mesh coarse powder, adding about 6 times of water, extracting at about 60 deg.C to obtain extractive solution A1; extracting the residue with about 3 times of 40% propylene glycol solvent at 70 deg.C to obtain extractive solution A2. Mixing the extractive solutions A1 and A2, filtering, and recovering solvent to obtain concentrated solution.

In some embodiments, the method comprises pulverizing the raw materials into 20 mesh coarse powder, adding about 5 times of water, extracting at about 80 deg.C to obtain extractive solution A1; extracting the residue with about 3 times of 40% ethanol solvent at 65 deg.C to obtain extractive solution A2. Mixing the extractive solutions A1 and A2, filtering, and recovering solvent to obtain concentrated solution.

In some embodiments, the method comprises pulverizing the raw materials into 20 mesh coarse powder, adding about 5 times of water, extracting at about 70 deg.C to obtain extractive solution A1; extracting the residue with about 4 times of 1:1 mixed solvent of 40% ethanol and 10% propylene glycol at 55 deg.C to obtain extractive solution A2. Mixing the extractive solutions A1 and A2, filtering, and recovering solvent to obtain concentrated solution.

In some embodiments, the method comprises respectively taking cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni Radicis, and herba Saxifragae, respectively taking the raw materials, pulverizing into 10 mesh coarse powder, adding about 6 times of water, extracting at about 60 deg.C to obtain extract A1; adding about 3 times of about 40% propylene glycol into the residue for extraction, wherein the extraction temperature is about 70 ℃ to obtain an extracting solution A2, combining the extracting solutions A1 and A2, mixing, filtering, recovering the solvent to obtain concentrated solutions of the extracts of the raw material medicines, and combining the concentrated solutions according to a certain weight percentage to obtain the traditional Chinese medicine compound composition. The certain proportion of the extracts is as follows: 12% of cortex moutan, 32% of honeysuckle, 20% of radix sophorae flavescentis, 36% of cortex dictamni and 2% of saxifrage. In some embodiments, the concentrate is adjusted with water. Further, the concentrate was adjusted to 1000g with water.

In some embodiments, the method comprises pulverizing cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni Radicis, and herba Saxifragae into 20 mesh coarse powder, respectively, adding about 5 times of water, and extracting at about 80 deg.C to obtain extractive solution A1; extracting the residue with about 3 times of about 40% ethanol at about 65 deg.C to obtain extractive solution A2. Mixing the extract solutions A1 and A2, filtering after mixing, recovering the solvent to obtain the concentrated solution of each raw material medicine extract, and combining according to a certain weight percentage to obtain the traditional Chinese medicine compound composition. The certain proportion of the extracts is as follows: cortex moutan 18%, honeysuckle 20%, radix sophorae flavescentis 28%, cortex dictamni 28% and saxifrage 6%. In some embodiments, the concentrate is adjusted with water. Further, the concentrate was adjusted to 1000g with water.

In some embodiments, the method comprises pulverizing cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni Radicis, and herba Saxifragae into 20 mesh coarse powder, respectively, adding about 5 times of water, and extracting at about 60 deg.C to obtain extractive solution A1; extracting the residue with about 4 times of mixed solvent of 10% ethanol and 40% propylene glycol at 1:1 ratio at 70 deg.C to obtain extractive solution A2. Mixing the extract solutions A1 and A2, filtering after mixing, recovering the solvent to obtain the concentrated solution of each raw material extract, and combining according to a certain weight percentage to obtain the traditional Chinese medicine compound composition. The certain proportion of the extracts is as follows by weight percent: cortex moutan 24%, honeysuckle flower 28%, radix sophorae flavescentis 20%, cortex dictamni 24% and saxifrage 4%. In some embodiments, the concentrate is adjusted with water. Further, the concentrate was adjusted to 1000g with water.

In some embodiments, the method comprises pulverizing cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni Radicis, and herba Saxifragae into 20 mesh coarse powder, respectively, adding about 5 times of water, and extracting at about 70 deg.C to obtain extractive solution A1; extracting the residue with about 4 times of mixed solvent of 40% ethanol and 10% propylene glycol at 1:1 ratio at 55 deg.C to obtain extractive solution A2. Mixing the extract solutions A1 and A2, filtering after mixing, recovering the solvent to obtain the concentrated solution of each raw material extract, and combining according to a certain weight percentage to obtain the traditional Chinese medicine compound composition. The certain proportion of the extracts is as follows by weight percent: cortex moutan 28%, honeysuckle flower 20%, radix sophorae flavescentis 24%, cortex dictamni 20% and saxifrage 8%. In some embodiments, the concentrate is adjusted with water. Further, the concentrate was adjusted to 1000g with water.

In some embodiments, the method comprises pulverizing cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni Radicis, and herba Saxifragae into 10 mesh coarse powder, respectively, adding about 6 times of water, and extracting at about 60 deg.C to obtain extract A1; extracting the residue with about 3 times of 40% propylene glycol solvent at 70 deg.C to obtain extractive solution A2. Mixing the extract solutions A1 and A2, filtering after mixing, recovering the solvent to obtain the concentrated solution of each raw material extract, and combining according to a certain weight percentage to obtain the traditional Chinese medicine compound composition. The certain proportion of the extracts is as follows: cortex moutan 24%, honeysuckle flower 28%, radix sophorae flavescentis 20%, cortex dictamni 24% and saxifrage 4%. In some embodiments, the concentrate is adjusted with water. Further, the concentrate was adjusted to 1000g with water.

In some embodiments, the method comprises pulverizing cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni Radicis, and herba Saxifragae into 20 mesh coarse powder, respectively, adding about 5 times of water, and extracting at about 80 deg.C to obtain extract A1; extracting the residue with about 3 times of 40% ethanol solvent at 65 deg.C to obtain extractive solution A2. Mixing the extract solutions A1 and A2, filtering after mixing, recovering the solvent to obtain the concentrated solution of each raw material extract, and combining according to a certain weight percentage to obtain the traditional Chinese medicine compound composition. The certain proportion of the extracts is as follows: cortex moutan 24%, honeysuckle flower 28%, radix sophorae flavescentis 20%, cortex dictamni 24% and saxifrage 4%. In some embodiments, the concentrate is adjusted with water. Further, the concentrate was adjusted to 1000g with water.

In some embodiments, the method comprises pulverizing cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni Radicis, and herba Saxifragae into 20 mesh coarse powder, respectively, adding about 5 times of water, and extracting at about 70 deg.C to obtain extract A1; extracting the residue with about 4 times of mixed solvent of 40% ethanol and 10% propylene glycol at 1:1 ratio at 55 deg.C to obtain extractive solution A2. Mixing the extract solutions A1 and A2, filtering after mixing, recovering the solvent to obtain the concentrated solution of each raw material extract, and combining according to a certain weight percentage to obtain the traditional Chinese medicine compound composition. The certain proportion of the extracts is as follows: cortex moutan 24%, honeysuckle flower 28%, radix sophorae flavescentis 20%, cortex dictamni 24% and saxifrage 4%. In some embodiments, the concentrate is adjusted with water. Further, the concentrate was adjusted to 1000g with water.

A third aspect of the present invention relates to the traditional Chinese medicine compound composition of the present invention obtained by the preparation method as defined in the second aspect of the present invention. In some embodiments, the herbal combination composition obtained by the method has antiallergic, antiinflammatory, redness relieving, antipruritic, anti-irritant and/or skin repairing effects. In some embodiments, the allergy, inflammation, redness, itching, irritation are caused by an inflammatory factor. In some embodiments, the inflammatory factor is IL-8 and NF-kb. In some embodiments, the herbal composition comprises moutan bark, lonicera japonica, sophora flavescens, dictamnus dasycarpus and/or saxifrage. Further, the traditional Chinese medicine compound composition is as defined in the first aspect of the invention.

In a fourth aspect, the present invention relates to a herbal composition for anti-allergy, anti-inflammatory, redness relief, itching relief, anti-irritation and/or skin repair. In some embodiments, the allergy, inflammation, redness, itching, irritation are caused by an inflammatory factor. In some embodiments, the inflammatory factor is IL-8 and NF-kb. In some embodiments, the herbal compound composition is as defined in the first aspect of the invention. In some embodiments, the herbal compound composition is a herbal compound composition obtained by the preparation method as defined in the third aspect of the present invention.

In a fifth aspect, the invention relates to the use of a herbal combination in a product for anti-allergy, anti-inflammatory, redness relief, itching relief, anti-irritation and/or skin repair. In some embodiments, the allergy, inflammation, redness, itching, irritation are caused by an inflammatory factor. In some embodiments, the inflammatory factor is IL-8 and NF-kb. In some embodiments, the herbal compound composition is as defined in the first aspect of the invention. In some embodiments, the herbal compound composition is a herbal compound composition obtained by the preparation method as defined in the third aspect of the present invention. In some embodiments, the product is a pharmaceutical formulation or a cosmetic.

In a sixth aspect, the present invention relates to a pharmaceutical preparation or a cosmetic, wherein the pharmaceutical preparation or the cosmetic comprises a herbal composition comprising or consisting of cortex moutan, flos lonicerae, radix sophorae flavescentis, cortex dictamni and/or saxifrage. In some embodiments, the pharmaceutical formulation or cosmetic has antiallergic, antiinflammatory, redness-relieving, antipruritic, anti-irritant and/or skin-repairing effects. In some embodiments, the allergy, inflammation, redness, itching, irritation are caused by an inflammatory factor. In some embodiments, the inflammatory factor is IL-8 and NF-kb. In some embodiments, the pharmaceutical formulation or cosmetic comprises a herbal combination composition as an active ingredient and one or more cosmetically or pharmaceutically acceptable carriers, diluents, or excipients. In some embodiments, the pharmaceutical formulation or cosmetic is a cream, lotion, paste, ointment, mask, gel, lotion, or serum. In some embodiments, the pharmaceutical or cosmetic formulation of the invention may also contain one or more other ingredients, such as plant extracts, nutritional additives, surfactants, fragrances and perfumes, pigments, preservatives, antioxidants, humectants, ultraviolet light absorbers, astringents, penetration aids, pH adjusters, and the like. The skilled person will be able to select them on the basis of their general knowledge and specific needs. In some embodiments, in the pharmaceutical preparation or cosmetic, the herbal composition comprises about 0.1-20%, preferably 2-15%, more preferably 5-10% by weight of the pharmaceutical preparation or cosmetic.

In a seventh aspect, the present invention relates to a cosmetic method comprising applying a herbal composition comprising cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni Radicis and/or herba Saxifragae. In some embodiments, the cosmetic method has anti-allergic, anti-inflammatory, redness-relieving, itching-relieving, anti-irritant, and/or skin-repairing effects. In some embodiments, the allergy, inflammation, redness, itching, irritation are caused by an inflammatory factor. In some embodiments, the inflammatory factor is IL-8 and NF-kb. In some embodiments, the present invention relates to a cosmetic method comprising applying a pharmaceutical preparation or cosmetic comprising the herbal compound composition. In some embodiments, the herbal compound composition is as defined in the first aspect of the invention. In some embodiments, the herbal compound composition is a herbal compound composition obtained by the preparation method as defined in the third aspect of the present invention. In some embodiments, the pharmaceutical formulation or cosmetic is as defined in the sixth aspect of the invention.

The invention has the following beneficial effects:

according to the traditional Chinese medicine compound composition containing cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and/or saxifrage, and the pharmaceutical preparation or the cosmetic containing the composition, which are disclosed by the invention, have unexpected technical effects, especially have strong antiallergic, anti-inflammatory, redness relieving, itching relieving, irritation resisting and/or skin repairing effects.

Alternatively, the individual raw materials may be extracted separately to obtain extracts, and the obtained extracts may be combined to obtain the extract composition of the present invention. The drug substance can be extracted by known extraction methods, but preferably, the extraction is performed by the method described in the specification of the present invention. The product prepared by the method has strong antiallergic, anti-inflammatory, redness relieving, itching relieving, irritation resisting and/or skin repairing effects, and is more stable, safer and free of side effects.

Detailed Description

The present invention can be carried out by the following embodiments, but the present invention is not limited thereto.

Percentages referred to in embodiments of the present invention are weight percentages unless explicitly indicated.

The instruments and equipment adopted in the embodiment of the invention are all conventional in the field and can be replaced by instruments and equipment meeting the corresponding standards.

Reagents used in embodiments of the invention are commercially available analytical grade reagents unless explicitly indicated.

The raw materials and the apparatuses mentioned in the present invention are all the raw materials and apparatuses commonly used in the art, and are only examples, and are not intended to limit the protection scope of the present invention. Those skilled in the art can select equivalent raw materials and related equipment based on the disclosure of the present invention.

1. Preparation of Chinese medicinal compound composition

Example 1

Taking 1000g of raw material medicines, wherein 12% of cortex moutan, 32% of honeysuckle, 20% of radix sophorae flavescentis, 36% of cortex dictamni and 2% of saxifrage are ground into 10-mesh coarse powder, and water with the amount of about 6 times of the coarse powder is added for extraction, and the extraction temperature is about 60 ℃ to obtain an extraction solution A1; extracting the residue with about 3 times of about 40% propylene glycol at about 70 deg.C to obtain extractive solution A2; mixing extractive solutions A1 and A2, filtering, recovering solvent to obtain concentrated solution, and adjusting with water to 1000g to obtain 100% extractive solution.

Example 2

Taking 1000g of raw material medicines, wherein the cortex moutan is 18%, the honeysuckle is 20%, the radix sophorae flavescentis is 28%, the cortex dictamni is 28% and the saxifrage is 6%, crushing into 20-mesh coarse powder, adding about 5 times of water for extraction, and extracting at the temperature of about 80 ℃ to obtain an extracting solution A1; extracting the residue with about 3 times of about 40% ethanol at about 65 deg.C to obtain extractive solution A2. Mixing extractive solutions A1 and A2, filtering, recovering solvent to obtain concentrated solution, and adjusting with water to 1000g to obtain 100% extractive solution.

Example 3

Taking 1000g of raw material medicines, wherein the cortex moutan is 24%, the honeysuckle is 28%, the radix sophorae flavescentis is 20%, the cortex dictamni is 24% and the saxifrage is 4%, crushing into 20-mesh coarse powder, adding about 5 times of water for extraction, and extracting at the temperature of about 60 ℃ to obtain an extracting solution A1; extracting the residue with about 4 times of mixed solvent of 10% ethanol and 40% propylene glycol at 1:1 ratio at 70 deg.C to obtain extractive solution A2. Mixing extractive solutions A1 and A2, filtering, recovering solvent to obtain concentrated solution, and adjusting with water to 1000g to obtain 100% extractive solution.

Example 4

Taking 1000g of raw material medicines, wherein the cortex moutan is 28%, the honeysuckle is 20%, the radix sophorae flavescentis is 24%, the cortex dictamni is 20% and the saxifrage is 8%, crushing into 20-mesh coarse powder, adding about 5 times of water for extraction, and extracting at the temperature of about 70 ℃ to obtain an extracting solution A1; extracting the residue with about 4 times of mixed solvent of 40% ethanol and 10% propylene glycol at 1:1 ratio at 55 deg.C to obtain extractive solution A2. Mixing extractive solutions A1 and A2, filtering, recovering solvent to obtain concentrated solution, and adjusting with water to 1000g to obtain 100% extractive solution.

Example 5

Taking 1000g of raw material medicines, wherein the cortex moutan is 24%, the honeysuckle is 28%, the radix sophorae flavescentis is 20%, the cortex dictamni is 24% and the saxifrage is 4%, crushing the raw material medicines into 10-mesh coarse powder, adding about 6 times of water for extraction, and extracting at the temperature of about 60 ℃ to obtain an extracting solution A1; extracting the residue with about 3 times of 40% propylene glycol solvent at 70 deg.C to obtain extractive solution A2. Mixing extractive solutions A1 and A2, filtering, recovering solvent to obtain concentrated solution, and adjusting with water to 1000g to obtain 100% extractive solution.

Example 6

Taking 1000g of raw material medicines, wherein the cortex moutan is 24%, the honeysuckle is 28%, the radix sophorae flavescentis is 20%, the cortex dictamni is 24% and the saxifrage is 4%, crushing into 20-mesh coarse powder, adding about 5 times of water for extraction, and extracting at the temperature of about 80 ℃ to obtain an extracting solution A1; extracting the residue with about 3 times of 40% ethanol solvent at 65 deg.C to obtain extractive solution A2. Mixing extractive solutions A1 and A2, filtering, recovering solvent to obtain concentrated solution, and adjusting with water to 1000g to obtain 100% extractive solution.

Example 7

Taking 1000g of raw material medicines, wherein the cortex moutan is 24%, the honeysuckle is 28%, the radix sophorae flavescentis is 20%, the cortex dictamni is 24% and the saxifrage is 4%, crushing into 20-mesh coarse powder, adding about 5 times of water for extraction, and extracting at the temperature of about 70 ℃ to obtain an extracting solution A1; extracting the residue with about 4 times of mixed solvent of 40% ethanol and 10% propylene glycol at 1:1 ratio at 55 deg.C to obtain extractive solution A2. Mixing extractive solutions A1 and A2, filtering, recovering solvent to obtain concentrated solution, and adjusting with water to 1000g to obtain 100% extractive solution.

Example 8

Respectively taking 1000g of raw material medicaments of cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and saxifrage, respectively extracting by the method in the embodiment 1 to finally obtain 1000g of cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and saxifrage extracting solutions with the marked concentration of 100%, and then combining the extracting solutions according to the proportion in the embodiment 1 to finally obtain the compound extracting solution with the marked concentration of 100%.

Example 9

Respectively taking 1000g of raw material medicaments of cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and saxifrage, respectively extracting by the method in the embodiment 2 to finally obtain 1000g of cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and saxifrage extracting solutions with the marked concentration of 100%, and then combining the extracting solutions according to the proportion in the embodiment 2 to finally obtain the compound extracting solution with the marked concentration of 100%.

Example 10

Respectively taking 1000g of raw material medicaments of cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and saxifrage, respectively extracting by the method in the embodiment 3 to finally obtain 1000g of cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and saxifrage extracting solutions with the marked concentration of 100%, and then combining the extracting solutions according to the proportion in the embodiment 3 to finally obtain the compound extracting solution with the marked concentration of 100%.

Example 11

Respectively taking 1000g of raw material medicaments of cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and saxifrage, respectively extracting by the method in the embodiment 4 to finally obtain 1000g of cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and saxifrage extracting solutions with the marked concentration of 100%, and then combining the extracting solutions according to the proportion in the embodiment 4 to finally obtain the compound extracting solution with the marked concentration of 100%.

Example 12

Respectively taking 1000g of raw material medicaments of cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and saxifrage, respectively extracting by the method in the embodiment 5 to finally obtain 1000g of cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and saxifrage extracting solutions with the marked concentration of 100%, and then combining the extracting solutions according to the proportion in the embodiment 5 to finally obtain the compound extracting solution with the marked concentration of 100%.

Example 13

Respectively taking 1000g of raw material medicaments of cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and saxifrage, respectively extracting by the method in the embodiment 6 to finally obtain 1000g of cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and saxifrage extracting solutions with the marked concentration of 100%, and then combining the extracting solutions according to the proportion in the embodiment 6 to finally obtain the compound extracting solution with the marked concentration of 100%.

Example 14

Respectively taking 1000g of raw material medicaments of cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and saxifrage, respectively extracting by the method in the embodiment 7 to finally obtain 1000g of cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and saxifrage extracting solutions with the marked concentration of 100%, and then combining the extracting solutions according to the proportion in the embodiment 7 to finally obtain the compound extracting solution with the marked concentration of 100%.

Comparative example 1

1000g of the raw material medicines are taken, wherein 26% of honeysuckle, 26% of radix sophorae flavescentis, 36% of cortex dictamni and 12% of saxifrage are extracted by a method similar to that in example 3.

Comparative example 2

1000g of the raw material medicines are taken, wherein 26% of cortex moutan, 28% of radix sophorae flavescentis, 38% of cortex dictamni and 8% of saxifrage are extracted by a method similar to that in example 3.

Comparative example 3

1000g of the raw material medicines are taken, wherein 26% of cortex moutan, 30% of honeysuckle, 34% of cortex dictamni and 10% of saxifrage are extracted by a method similar to that in example 3.

Comparative example 4

1000g of the raw material medicines are taken, wherein 28% of cortex moutan, 32% of honeysuckle, 28% of radix sophorae flavescentis and 12% of saxifrage are extracted by a method similar to that in example 3.

2. In vivo efficacy test comparison

And (3) reagent sources: sodium dodecyl sulfate (Adamas), hydrocortisone cream (Hunan Dino pharmaceuticals, Inc.), dextran (Adamas), xylene (great)

Preparing a reagent:

5% (w/w) of each sample tested in the examples: 5% (w/w) of each sample to be tested in examples were prepared by adding 5g of the 100% labeled extract prepared in examples 1 to 4 to 95g of physiological saline.

5% (w/w) of each of the samples tested in comparative examples: 5% (w/w) of each sample to be tested in comparative example was prepared by adding 5g of the 100% strength extract prepared in comparative example 1 to 4 to 95g of physiological saline.

(1) Anti-allergy test experiment (irritation guinea pig)

5% sodium dodecyl sulfate was used as a model group, hydrocortisone cream (specification: 100g/10mg) was used as a positive control group, and the dose was 0.1 g/mouse. Physiological saline is used as a negative control sample (negative control modeling group), the experimental sample group is 5% (w/w) of the samples to be tested of each example or comparative example, and the dosage is 0.5 g/sample. Samples of an experimental group, a positive control group and a negative control group are respectively mixed with 5% of sodium dodecyl sulfate, and the mixture is smeared and observed according to a multi-time skin irritation test method of technical Specification for cosmetic safety 2015, wherein P490-491, 6 guinea pigs in each group have half of male and female. The red and swollen state of the applied part is observed. The red and swollen are 4-5 points, the slight red and swollen are 1-3 points, and the unchanged point is 0 point.

(2) Anti-allergy test experiment (dextran method)

Healthy mice with the weight of 18-22 g are divided into halves and males at random according to the sex and the weight, and each group contains 10 mice. The animal's back hair was removed with 1% sodium sulfide and the area of the skin area to be removed was 1.5cm x 1.5cm, and was used for the experiment after 2 days. The hair removal area of the back of each group of animals is respectively and locally coated with a sample to be tested (1 g/kg). Hydrocortisone cream (specification: 100g/10mg) was used as a positive control group at a dose of 0.1 g/mouse. Saline was used as a negative control sample (negative control model), and the experimental sample group was 5% (w/w) of the extract prepared in example or comparative example. For 5 consecutive days, each mouse was injected with dextran 0.95mg/kg in the tail vein 30min after the last administration. Taking the head of the mouse scratched with the front paw, the trunk of the mouse with the back paw and the whole body bitten by the mouth as itching indications, and recording the itching times of the mouse within 30 minutes.

The pruritus inhibition rate is (pruritus times of the negative control group-pruritus times of the sample group) ÷ pruritus times of the negative control group 100%.

(3) Anti-inflammatory test experiment (xylene-induced ear swelling experiment for mice)

Healthy mice with the weight of 18-22 g are divided into halves and males at random according to the sex and the weight, and each group contains 10 mice. The right ear of the mouse was smeared with each corresponding group of samples to be tested, 0.2 g/mouse, once a day for 3 consecutive days. Hydrocortisone cream (specification: 100g/10mg) was used as a positive control group at a dose of 0.1 g/mouse. Saline was used as a negative control sample (negative control model), and the experimental sample group was 5% (w/w) of the extract prepared in example or comparative example. 30min after the last application, 0.02 ml/mouse left ear was left without any treatment, the animals were sacrificed 4 hours later, both ears were immediately cut off, the same part of the ear was taken with an 8mm punch, and the ear was weighed on an analytical balance, and the swelling degree was determined by subtracting the weight of the left ear from the weight of the right ear, and the ear swelling rate was determined by (weight of right ear-weight of left ear)/weight of left ear × 100%.

Results of the experiment

TABLE 1 anti-allergic anti-inflammatory test results

As can be seen from the above results, the Chinese herbal compound composition containing specific components claimed by the present invention has synergistic effects in anti-allergy, anti-inflammatory, anti-itching, anti-irritation and/or skin repair.

3. In vitro efficacy test comparison

(1) Anti-inflammatory assay (study of inhibition of inflammatory factor IL-8)

N-Hacat cells, DMEM culture Solution (SIGMA), serum, an incubator (Sammerfei), a fluorescence microplate reader (MEUG MD), an IL-8 detection kit (SIGMA), cell lysate, DPBS (Dulbecco phosphate buffer solution), pancreatin (SIGMA) and a 96-well plate.

Sample to be tested

Test samples of example 3: the sample concentration was 0.05%, 0.1%, 0.5% (v/v). An appropriate amount of the extract solution having the concentration indicated as 100% prepared in example 3 was added to a DMEM culture solution to prepare a sample having the above volume concentration.

Comparative examples 1 to 4 were prepared in the same manner as the samples to be tested. The sample concentrations were 0.05%, 0.1%, 0.5%.

Reagent: epigallocatechin gallate (EGCG, 50uM), TNF-alpha (10 ng/ml).

Experimental methods

Taking out cultured N-Hacat cells from the incubator, digesting and centrifuging to obtain suspension, and adjusting cell density to 1 × 10⁵One/ml to 5 x 10⁵And (4) inoculating 135 mu l of the culture medium into a 96-well plate per ml, and continuing to culture for 12-24 h. After the culture, 15. mu.l of each prepared sample (the extract of example 3, the extracts of comparative examples 1 to 4, EGCG, and DPBS as negative control) was added to the well plate at each concentration, and after the culture continued for 12 to 24 hours, 16.5. mu.l of TNF-. alpha.was added to each well of the well plate (16.5. mu.l of DPBS was added to each well of the control group). Culturing for 12-24h, collecting culture solution after culturing, detecting with IL-8 detection kit (purchased from SIGMA), and placing into fluorescence enzyme labeling instrument to read at OD450 nm.

Results of the experiment

The experimental results show that the extract of example 3 and the extracts of comparative examples 1 to 4 have a certain inhibition effect on the release of the inflammatory factor IL-8. With increasing concentration, example 3 showed more significant inhibition P <0.001 on the release of the inflammatory factor IL-8, and was dose dependent. However, the comparative examples showed no significant inhibition of the release of the inflammatory factor IL-8. For specific experimental data, see fig. 1.

(2) Anti-inflammatory assay (study of inhibition of inflammatory factor NF-kb)

Experiment reagent and equipment

N-Hacat cells, DMEM culture Solution (SIGMA), serum, incubator (sermer fly), luciferase reader (metgu MD), luciferase assay kit (purchased from shanghai yiying biotechnology limited), cell lysate (obtained from luciferase assay kit), DPBS (Dulbecco phosphate buffered saline), pancreatin (SIGMA), 96-well plate.

Sample to be tested

Test samples of example 3: the sample concentration was 0.05%, 0.1%, 0.5% (v/v). An appropriate amount of the extract solution labeled with 100% concentration prepared in example 3 was added to a DMEM culture solution to prepare a sample to be measured having the above volume concentration.

Comparative examples 1 to 4 were prepared in the same manner as the test samples. The sample concentrations were 0.05%, 0.1%, 0.5%.

Experimental methods

Taking out cultured N-Hacat cells from the incubator, digesting and centrifuging to obtain suspension, and adjusting cell density to 1 × 10⁵One/ml to 5 x 10⁵And (4) inoculating 135 mu l of the culture medium into a 96-well plate per ml, and continuing to culture for 12-24 h. After the culture, 15. mu.l of each prepared sample (the mixed extract of example 3, the extracts of comparative examples 1 to 4, EGCG, and DPBS as negative control) was added to the well plate at each concentration, and after the culture continued for 12 to 24 hours, 16.5. mu.l of TNF-. alpha.was added to each well of the well plate (16.5. mu.l of DPBS was added to each well of the control group). The culture is continued for 12-24h, after the culture is finished, 100 μ l of lysate (obtained from luciferase assay kit, see kit instructions) is added into each well of the well plate, the operation is carried out according to the instructions of the luciferase assay kit (obtained from Shanghai Ying Biotechnology Co., Ltd.), and the reading is carried out in a Lum mode of a fluorescence microplate reader.

Results of the experiment

Experimental results show that the extract in example 3 and the extracts in comparative examples 1 to 4 have a certain inhibition effect on the expression of the inflammatory factor NF-kb. With increasing concentration, example 3 showed more significant inhibition P <0.001 on the expression of the inflammatory factor NF-kb, and was dose-dependent. However, the comparative example group did not show significant inhibition of the expression of the inflammatory factor NF-kb. See fig. 2 for specific experimental data.

4. Human body efficacy test experiment

Purpose of testing

The ability of the solution of example 3 to soothe redness was evaluated by a closed patch-induced red model and compared to the soothing efficacy of comparative examples 1-4 at the same concentration, intended to demonstrate the synergistic efficacy of the compound composition of example 3.

Materials and methods

The subjects are healthy Chinese people of 19-60 years old, and meet the technical Specification for cosmetic safety 2015 edition, the selection of the subjects in the skin patch test of 5, P541.

Test sample

Red-causing mold making medicine: sodium dodecyl Sulfate (SIGMA)

A plaque chamber device: finn Chamber 8mm

Test samples of example 3: as described in the reagent preparation in the body function test comparison, an appropriate amount of the extract solution with the labeled concentration of 100% prepared in example 3 was added to the blank emulsion to prepare a sample to be tested with the required weight concentration, i.e., 5% (w/w).

The samples to be tested of comparative examples 1 to 4 were prepared in the same manner.

Experimental methods

Subjects were subjected to a skin screen (BL) of the back test area by staff. And selecting a skin area without influence evaluation factors for spot pasting. An erythropoiesis molding agent, namely sodium dodecyl sulfate, is added into each small hole of the macula device. And applied to the back for 24 hours. In order to prevent the spot tester from falling off, the periphery of the spot tester can be fixed by medical adhesive tapes.

After 24 hours, the reddening modeling drug is removed, and the clinical dermatologist evaluates the skin reaction grading standard of the skin closed patch experiment shown in the table 1 of the method 6 in the human skin patch test according to the technical Specification for cosmetic safety 2015 edition (after reddening-T0.5). Samples were divided into 6 groups: blank (water) group, 5% of example 3, 5% of comparative examples 1-4. Equal amounts of samples were added to the different chamber chambers and were removed 24 hours after application to the reddish area and again evaluated by the clinical dermatologist (post-relief-T24).

Results of the experiment

The establishment of the erythropoiesis model of 32 subjects and the efficacy evaluation of the degree of the relieved redness of 6 groups of samples are effectively completed, and the results show that:

example 3 evaluation values of redness of skin after the treatment of the sample to be tested are obviously reduced, and there is a significant difference (p is less than 0.05), which shows that the sample to be tested in example 3 has obvious relieving effect on the symptoms of redness of skin. The redness values before and after relaxation of comparative examples 1-4 were not significantly different (p > 0.05), indicating that the extracts of the comparative examples had no relief effect on the symptoms of skin redness at these concentrations.

The blank control (water) showed no significant change in the redness values before and after the effect, indicating that water as the sample diluent had no effect on the extent of redness alleviation. In conclusion, the 5% solution of example 3 can remarkably relieve the redness symptom of the skin, but the effect of the extract of the comparative example under the same concentration is not obvious, which shows that the traditional Chinese medicine compound composition containing the specific components claimed by the invention has a synergistic effect on relieving the redness degree. See fig. 3 for specific experimental data.

Claims

1. A traditional Chinese medicine compound composition comprises the following raw material medicines: cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and/or saxifrage, or the composition contains the following extracts of raw material medicines: cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni Radicis and/or herba Saxifragae.

2. The compound traditional Chinese medicine composition according to claim 1, wherein the composition comprises the following raw material medicines in percentage by weight: 10-30% of cortex moutan, 20-40% of honeysuckle, 20-40% of radix sophorae flavescentis, 20-60% of cortex dictamni and 0-20% of saxifrage, or the composition contains the following raw material medicine extracts in percentage by weight: 0-40% of cortex moutan, 0-60% of honeysuckle, 0-60% of radix sophorae flavescentis, 0-80% of cortex dictamni and/or 0-40% of saxifrage.

3. A method of preparing the herbal compound composition of any one of claims 1-2, the method comprising:

weighing and crushing raw material medicines, wherein the raw material medicines comprise cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and/or saxifrage; extracting pulverized raw materials with water, extracting with 10% -70% C2-6 alcohol water solution, and mixing the two extracts to obtain extract composition, or

Weighing raw materials, and pulverizing, wherein the raw materials comprise cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni Radicis and/or herba Saxifragae; the crushed raw materials are respectively extracted according to the following methods: extracting with water, extracting with 10% -70% C2-6 alcohol aqueous solution, mixing the two extracts to obtain separate medicinal material extracts, and mixing the separate medicinal material extracts to obtain the extract composition.

4. The method of claim 3, wherein the C2-6 alcohol is ethanol, propanol, propylene glycol, n-butanol, or a combination thereof; extracting with water at 50-100 deg.C; the extraction temperature with 10-70% C2-6 alcohol aqueous solution is 40-85 deg.C.

5. The method of claim 3 or 4, further comprising purifying the resulting extract composition by filtration to obtain a concentrate.

6. The compound Chinese medicinal composition prepared by the method according to claim 3 or 4.

7. Use of a herbal combination according to any one of claims 1-2 and 6 for the manufacture of a product for anti-allergic, anti-inflammatory, redness relief, itching relief, anti-irritation and/or skin repair.

8. A pharmaceutical preparation or cosmetic comprising the herbal pharmaceutical combination according to any one of claims 1-2 and 6 as an active ingredient together with one or more cosmetically or pharmaceutically acceptable carriers, diluents or excipients.

9. The pharmaceutical formulation or cosmetic of claim 8, wherein the pharmaceutical formulation or cosmetic is a cream, lotion, paste, ointment, mask, gel, lotion, or serum.

10. The pharmaceutical formulation or cosmetic of claim 8 or 9, wherein the herbal composition comprises about 0.1-20% by weight of the pharmaceutical formulation or cosmetic.